Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) EPS (Basic) (2024 - 2025)

Kairos Pharma's EPS (Basic) history spans 2 years, with the latest figure at -$0.07 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 12.5% year-over-year to -$0.07; the TTM value through Dec 2025 reached -$0.31, down 34.78%, while the annual FY2025 figure was -$0.3, 30.43% down from the prior year.
  • EPS (Basic) reached -$0.07 in Q4 2025 per KAPA's latest filing, up from -$0.08 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.02 in Q2 2024 to a low of -$0.1 in Q3 2024.